Related references
Note: Only part of the references are listed.The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer
P. de Graeff et al.
BRITISH JOURNAL OF CANCER (2008)
Prognostic value of hormonal receptors, p53, ki67 and HER2/neu expression in epithelial ovarian carcinoma
Adelaida Garcia-Velasco et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2008)
Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival
Frank Bartel et al.
CLINICAL CANCER RESEARCH (2008)
New therapies for ovarian cancer: Cytotoxics and molecularly targeted agents
Phuong Dinh et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2008)
Prognostic versus predictive value of biomarkers in oncology
C. N. A. M. Oldenhuis et al.
EUROPEAN JOURNAL OF CANCER (2008)
Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers: A Gynecologic Oncology Group study
Kathleen M. Darcy et al.
GYNECOLOGIC ONCOLOGY (2008)
Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation
Ninke Leffers et al.
GYNECOLOGIC ONCOLOGY (2008)
Decreased survival in EGFR gene amplified vulvar carcinoma
Whitfield B. Growdon et al.
GYNECOLOGIC ONCOLOGY (2008)
Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma
Marketa Tomsova et al.
GYNECOLOGIC ONCOLOGY (2008)
Epidermal growth factor receptor expression in serous ovarian carcinoma: An immunohistochemical study with galectin-3 and cyclin D1 and outcome
Hermann Brustmann
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2008)
Human papilloma virus (HPV) status, p16(INK4a), and p53 overexpression in epithelial malignant and borderline ovarian neoplasms
Glovanna Giordano et al.
PATHOLOGY RESEARCH AND PRACTICE (2008)
Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies
Martin Koebel et al.
PLOS MEDICINE (2008)
Combination of serum hCGβ and p53 tissue expression defines distinct subgroups of serous ovarian carcinoma
Juhani Vartiainen et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients
Marianne Tuefferd et al.
PLOS ONE (2007)
Epidermal growth factor receptor is involved in the development of an invasive phenotype in Vulvar squamous lesions, but is not related to MIB-1 immunoreactivity
Hermann Brustmann
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2007)
Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study
William E. Winter et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer
K. D. Steffensen et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2007)
Analysis of p53 protein expression levels on ovarian cancer tissue microarray using automated quantitative analysis elucidates prognostic patient subsets
A. Psyrri et al.
ANNALS OF ONCOLOGY (2007)
Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas
Vijaya Galic et al.
GENES CHROMOSOMES & CANCER (2007)
In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway
D. Pils et al.
BRITISH JOURNAL OF CANCER (2007)
Phosphorylated 4E binding protein 1: A hallmark of cell signaling that correlates with survival in ovarian cancer
Josep Castellvi et al.
CANCER (2006)
Alterations in the p53 pathway and prognosis in advanced ovarian cancer: A multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865)
J. A. Green et al.
EUROPEAN JOURNAL OF CANCER (2006)
Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin
Yuko Ueno et al.
CANCER LETTERS (2006)
Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies
P. de Graeff et al.
BRITISH JOURNAL OF CANCER (2006)
Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma
Heini Lassus et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2006)
Expression of cyclooxygenase-2 in epithelial ovarian tumors and its relation to vascular endothelial growth factor and p53 expression
JS Lee et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2006)
Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas
E Yakirevich et al.
GYNECOLOGIC ONCOLOGY (2006)
Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas
Christine H. Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Linking oncogenic pathways with therapeutic opportunities
Andrea H. Bild et al.
NATURE REVIEWS CANCER (2006)
Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer
A Psyrri et al.
CLINICAL CANCER RESEARCH (2005)
Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer:: Evidence for a crucial p53-p73 cross-talk in vivo
N Concin et al.
CLINICAL CANCER RESEARCH (2005)
Prognostic factors in ovarian carcinoma stage III patients.: Can biomarkers improve the prediction of short- and long-term survivors?
J Kaern et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2005)
Retinoid receptors in ovarian cancer:: expression and prognosis
PC Kaiser et al.
ANNALS OF ONCOLOGY (2005)
REporting recommendations for tumour MARKer prognostic studies (REMARK)
LM McShane et al.
BRITISH JOURNAL OF CANCER (2005)
Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic oncology group study
RJ Schilder et al.
CLINICAL CANCER RESEARCH (2005)
Language of publication restrictions in systematic reviews gave different results depending on whether the intervention was conventional or complementary
B Pham et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2005)
The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer
MJ Goodheart et al.
CLINICAL CANCER RESEARCH (2005)
Correlation of epidermal growth factor receptor expression with tumor microdensity vessels and with vascular endothelial growth factor expression in ovarian carcinoma
MR Raspollini et al.
INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY (2005)
HER2/neu oncoprotein overexpression in epithelial ovarian cancer: Evaluation of its prevalence and prognostic significance - Clinical study
E Verri et al.
ONCOLOGY (2005)
Expression of the c-myc gene as a predictor of chemotherapy response and a prognostic factor in patients with ovarian cancer
T Iba et al.
CANCER SCIENCE (2004)
Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer
SS Seo et al.
GYNECOLOGIC ONCOLOGY (2004)
Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group)
C Elie et al.
BRITISH JOURNAL OF CANCER (2004)
Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer
A Bali et al.
CLINICAL CANCER RESEARCH (2004)
Cancer of the ovary
SA Cannistra
NEW ENGLAND JOURNAL OF MEDICINE (2004)
ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma
H Lassus et al.
GYNECOLOGIC ONCOLOGY (2004)
Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer
JS Nielsen et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2004)
HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group
S Camilleri-Broet et al.
ANNALS OF ONCOLOGY (2004)
Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: A Gynecologic Oncology Group Study
L Havrilesky et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Independence of the prognostic value of tumor suppressor protein expression in ovarian adenocarcinomas: A multivariate analysis of expression of p53, retinoblastoma, and related proteins
M Tachibana et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2003)
Prognostic factors in ovarian cancer: current evidence and future prospects
APG Crijns et al.
EJC SUPPLEMENTS (2003)
Prognostic value of overexpression of p53 in human ovarian carcinoma patients receiving cisplatin
K Nakayama et al.
CANCER LETTERS (2003)
Reduced retinoblastoma gene protein to Ki-67 ratio is an adverse prognostic indicator for ovarian adenocarcinoma patients
AE Konstantinidou et al.
GYNECOLOGIC ONCOLOGY (2003)
Multivariate analysis for prognostic significance of histologic subtype, GST-pi, MDR-1, and p53 in stages II-IV ovarian cancer
K Ikeda et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2003)
P53 and Bcl-2 as prognostic predictors in epithelial ovarian cancer
RAM Sagarra et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2002)
Correlation of p53 immunostaining in primary and residual ovarian cancer at the time of positive second-look laparotomy and its prognostic role: A Southwest Oncology Group ancillary study
D Hawes et al.
GYNECOLOGIC ONCOLOGY (2002)
How should meta-regression analyses be undertaken and interpreted?
SG Thompson et al.
STATISTICS IN MEDICINE (2002)
Quantifying heterogeneity in a meta-analysis
JPT Higgins et al.
STATISTICS IN MEDICINE (2002)
Heterogeneity of ovarian cancer: Relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival
M Pieretti et al.
CANCER INVESTIGATION (2002)
Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer:: a multifactorial analysis of TP53, p21, BAX and BCL-2
M Schuyer et al.
BRITISH JOURNAL OF CANCER (2001)
The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma
I Skirnisdóttir et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2001)
P53, bcl-2, and bax:: Their relationship and effect on prognosis in early stage epithelial ovarian carcinoma
I Skirnisdóttir et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2001)
Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma
I Vergote et al.
LANCET (2001)
E-cadherin complex protein expression and survival in ovarian carcinoma
B Davidson et al.
GYNECOLOGIC ONCOLOGY (2000)
Prognostic significance of cell cycle proteins and genomic instability in borderline, early and advanced stage ovarian carcinomas
H Blegen et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2000)
Prognostic factors in early-onset epithelial ovarian cancer: A population-based study
JM Schildkraut et al.
OBSTETRICS AND GYNECOLOGY (2000)
Share Paper
